

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act (SMDA) of 1990 and 21 CFR 807.92. All data included in this document is accurate and complete to the best of KSEA's knowledge.

Applicant: Karl Storz Endoscopy - America, Inc.
600 Corporate Pointe Drive
Culver City, CA 90230
(310) 558-1500

Contact: Kevin Kennan
Regulatory Affairs Specialist

Device Identification: **Common Name:**
Endoscope

Trade Name: (optional)
Karl Storz Direct Coupled Interface (DCI) Endoscope

Indication: The KSEA DCI Endoscope is indicated for use during gynecologic laparoscopic surgical procedures, and, using additional accessories, to perform various diagnostic and therapeutic procedures.


Specific Indications for Use

- unexplained pelvic pain (acute, chronic)
- infertility work-up
- tubal sterilization
- unexplained primary or secondary amenorrhea
- diagnosis and/or treatment of ectopic pregnancy
- evaluation, diagnosis and/or treatment of small pelvic tumors, including myomata
- evaluation of congenital anomalies of the pelvic organs
- retrieval of foreign bodies
- determination of the presence and extent of pelvic endometriosis
- determination of the presence and extent of pelvic inflammatory disease
- laparoscopic assisted vaginal hysterectomy
- visualization, diagnosis and/or treatment of perforate abdominal organs

Device Description: The KSEA DCI Endoscope is comprised of a rigid, panoramic telescope which utilizes rod lens technology. The body contact portions of the KSEA DCI Endoscope are composed of surgical grade stainless steel, which is commonly used in medical devices for a wide range of applications and has a long history of biocompatibility for human use.

Substantial Equivalence: The KSEA DCI Endoscope is substantially equivalent to the predicate devices since the basic features, design and intended uses are the same. The minor differences between the KSEA DCI Endoscope and the predicate devices raise no new issues of safety and effectiveness, as these design differences have no affect on the performance, function or intended use of the devices.

Signed:


Kevin Kenan
Senior Regulatory Affairs Specialist



APR 2 1999

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Kevin A. Kennan
Senior Regulatory Affairs Specialist
Karl Storz Endoscopy – America, Inc.
600 Corporate Pointe
Culver City, CA 90230-7600

Re: K990004
Karl Storz Direct Coupled
Interface (DCI) Endoscope
(for Gynecologic Laparoscopy)
Dated: September 23, 1998
Received: January 4, 1999
Regulatory Class: II
21 CFR 884.1720/Procode: 85 HET

Dear Mr. Kennan:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

CAPT Daniel G. Schultz, M.D.
Acting Director, Division of Reproductive,
Abdominal, Ear, Nose and Throat,
and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K990004

Device Name: Karl Storz Direct Coupled Interface (DCI) Endoscope

Indications for Use: This instrument is indicated for use during gynecologic laparoscopic surgical procedures, and, using additional accessories, to perform various diagnostic and therapeutic procedures.

Specific Indications for Use


- unexplained pelvic pain (acute, chronic)
- infertility work-up
- tubal sterilization
- unexplained primary or secondary amenorrhea
- diagnosis and/or treatment of ectopic pregnancy
- evaluation, diagnosis and/or treatment of small pelvic tumors, including myomata
- evaluation of congenital anomalies of the pelvic organs
- retrieval of foreign bodies
- determination of the presence and extent of pelvic endometriosis
- determination of the presence and extent of pelvic inflammatory disease
- laparoscopic assisted vaginal hysterectomy
- visualization, diagnosis and/or treatment of perforate abdominal organs

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE
IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use: OR Over-The-Counter Use:
(Per 21 CFR 801.109)

(Optional Format 1-2-96)



(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K990004